A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

Abstract excerpt

BACKGROUND: To determine the prevalence of RET rearrangement genes, RET copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer (NSCLC) trials of vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling, and to determine any association with outcome to vandetanib treatment. METHODS: Archival tumor samples from the ZODIAC ( NCT00312377 , vandetanib ± docetaxel),...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Diagnosis and Treatment
• Share to Lung Cancer Treatments and Mutations
• Share to Radiomics and Machine Learning in Medical Imaging